GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (NAS:ABMD) » Definitions » ROA %

Abiomed (Abiomed) ROA % : 24.97% (As of Sep. 2022)


View and export this data going back to 1987. Start your Free Trial

What is Abiomed ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Abiomed's annualized Net Income for the quarter that ended in Sep. 2022 was $425 Mil. Abiomed's average Total Assets over the quarter that ended in Sep. 2022 was $1,700 Mil. Therefore, Abiomed's annualized ROA % for the quarter that ended in Sep. 2022 was 24.97%.

The historical rank and industry rank for Abiomed's ROA % or its related term are showing as below:

ABMD' s ROA % Range Over the Past 10 Years
Min: 3.92   Med: 13.67   Max: 41.81
Current: 16.27

During the past 13 years, Abiomed's highest ROA % was 41.81%. The lowest was 3.92%. And the median was 13.67%.

ABMD's ROA % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -1.84 vs ABMD: 16.27

Abiomed ROA % Historical Data

The historical data trend for Abiomed's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abiomed ROA % Chart

Abiomed Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.78 28.14 17.88 16.64 8.62

Abiomed Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.25 11.72 14.78 12.92 24.97

Competitive Comparison of Abiomed's ROA %

For the Medical Devices subindustry, Abiomed's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abiomed's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abiomed's ROA % distribution charts can be found below:

* The bar in red indicates where Abiomed's ROA % falls into.



Abiomed ROA % Calculation

Abiomed's annualized ROA % for the fiscal year that ended in Mar. 2022 is calculated as:

ROA %=Net Income (A: Mar. 2022 )/( (Total Assets (A: Mar. 2021 )+Total Assets (A: Mar. 2022 ))/ count )
=136.505/( (1494.359+1673.393)/ 2 )
=136.505/1583.876
=8.62 %

Abiomed's annualized ROA % for the quarter that ended in Sep. 2022 is calculated as:

ROA %=Net Income (Q: Sep. 2022 )/( (Total Assets (Q: Jun. 2022 )+Total Assets (Q: Sep. 2022 ))/ count )
=424.532/( (1703.636+1696.544)/ 2 )
=424.532/1700.09
=24.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2022) net income data. ROA % is displayed in the 30-year financial page.


Abiomed  (NAS:ABMD) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2022 )
=Net Income/Total Assets
=424.532/1700.09
=(Net Income / Revenue)*(Revenue / Total Assets)
=(424.532 / 1063.684)*(1063.684 / 1700.09)
=Net Margin %*Asset Turnover
=39.91 %*0.6257
=24.97 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Abiomed ROA % Related Terms

Thank you for viewing the detailed overview of Abiomed's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abiomed (Abiomed) Business Description

Traded in Other Exchanges
N/A
Address
22 Cherry Hill Drive, Danvers, MA, USA, 01923
Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.
Executives
Matthew T. Plano officer: VP, GLOBAL OPERATIONS C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Martin P Sutter director 2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380
David M Weber officer: Chief Operating Officer 2341 ROMANO CIRCLE, PLEASANTON CA 94566
Todd A Trapp officer: Vice President, CFO C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845
Michael R Minogue director, officer: President & CEO 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Myron L Rolle director 1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Andrew J Greenfield officer: VP Healthcare Solutions 14 HILLSIDE DRIVE, GEORGETOWN MA 01833
Marc A Began officer: VP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Michael G Howley officer: Vice President 22 CHERRY HILL DRIVE, DANVERS MA 01923
William J Bolt officer: SVP, DA and QA C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Henri A Termeer director ONE KENDALL SQUARE, CAMBRIDGE MA 02139

Abiomed (Abiomed) Headlines